NASDAQ: CASI | 中文 | Contact Us


CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation

December 23, 2020

The Chinese Center for Drug Evaluation, a division of the China National Medical Products Association, has granted Breakthrough Therapy Designation (“Breakthrough Designation”) to its partner Juventas Cell Therapy Ltd. for CNCT19, a potential CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). CASI has co-commercial rights to CNCT19 and is a shareholder of Juventas.

Appointment of Weihao Xu to the position of Chief Financial Officer

December 16, 2020

“We are very pleased to welcome Weihao to our leadership team. His unique experience encompasses both that of a healthcare-focused buy-side professional and of a CFO overseeing financial operations, including areas of financial planning and fundraising. These skills will enable him to significantly contribute to driving a number of our planned strategic initiatives forward in 2021 and beyond,” said Dr. He.

U.S. FDA-Approved Products In-Licensed for the Greater China Region


Multiple Myeloma


Non-Hodgkin's Lymphoma


Acute Lymphoblastic Leukemia

Pre-Clinical Candidates


Hematological Malignancies


Non-Hodgkin's Lymphoma and Solid Tumors


Multiple Myeloma
Learn more about our product pipeline

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More